57764-49-5

Usage

Uses

Used in Pharmaceutical Synthesis:
1,2-Benzisoxazole-3-carboxylic acid ethyl ester is used as a key intermediate in the pharmaceutical industry for the synthesis of various drugs and organic compounds. Its unique structure and properties allow it to be easily incorporated into complex molecular frameworks, contributing to the development of new and effective medications.
Used in Organic Chemistry:
In the field of organic chemistry, 1,2-benzisoxazole-3-carboxylic acid ethyl ester is utilized as a versatile building block for the synthesis of a wide range of organic compounds. Its reactivity and compatibility with various chemical reactions make it an ideal candidate for the creation of novel molecules with potential applications in various industries.
Used in Biologically Active Substances Production:
Due to its unique chemical and biological properties, 1,2-benzisoxazole-3-carboxylic acid ethyl ester is also employed as an intermediate in the production of biologically active substances. Its structure allows for the development of compounds with potential therapeutic effects, contributing to advancements in medicine and healthcare.

InChI:InChI=1/C10H9NO3/c1-2-13-10(12)9-7-5-3-4-6-8(7)14-11-9/h3-6H,2H2,1H3

Upstream product

• 57764-48-4 hydroxyimino-(2-nitro-phenyl)-acetic acid ethyl ester 
• 3740-52-1 2-(2-nitrophenyl)acetic acid 
• 651780-27-7 ethyl 6-bromobenzo[d]isoxazole-3-carboxylate 
• 31912-02-4 ethyl 2-nitrophenylacetate 

Downstream Products

• 668969-99-1 methyl 5-bromo-2-({[5-(chlorosulfonyl)-1,2-benzisoxazole-3-yl]carbonyl}amino)-5-cyanobenzoate 
• 1082682-56-1 methyl benzo[d]isoxazole-3-carboxylate 
• 75290-76-5 1-(benzo[d]isoxazol-3-yl)ethanone 
• 28691-51-2 3-carboxy-5-nitro-1,2-benzisoxazole 
• 28691-47-6 benzisoxazole-3-carboxylic acid 

Relevant academic research and scientific papers

CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.

INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

VLA-4 INHIBITORS

The present invention relates to a compound represented by the following formula (I): (wherein, W represents WA-A1 -WB - (in which, WA is substituted or unsubstituted aryl, etc., A1 is -NR1-, single bond, -C(O)-, etc., and WB is substituted or unsubstituted arylene, etc.), R is single bond, -NH-, -OCH2-, alkenylene, etc., X is -C(O) -CH2-, etc., and M is, for example, the following formula: (in which, R11, R12 and R13 each independently represents hydrogen, hydroxyl, amino, halogen, etc., R14 is hydrogen or lower alkyl, Y represents -CH2-O-, etc., Z is substituted or unsubstituted arylene, etc., A2 is single bond, etc, and R10 is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VAL-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.

Benzisoxazole- and Benzisothiazole-3-carboxamides as Potential Atypical Antipsychotic Agents

A series of benzisoxazole- and benzisothiazole-3-carboxamides has been prepared and tested for potential antipsychotic activity.In general, the compounds showed an affinity for dopamine D2 and serotonin 5HT2A and 5HT1A rec

Phytotoxic 2-alkyl-5-(heterocyclic)-pyrrole-3,4-dicarboxylates

Phytotoxic 2-methyl-5-(heterocyclic)-pyrrole-3,4-dicarboxylates.